Dynavax Technologies reported $92.2M in Operating Expenses for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Abbvie ABBV:US $ 10036M 518M
Adma Biologics ADMA:US $ 35.12M 1.71M
Alexion Pharmaceuticals ALXN:US $ 1000.3M 30.6M
Amgen AMGN:US $ 4.33B 1.37B
AstraZeneca AZN:LN 11.54B 4.45B
Astrazeneca AZN:US 11.54B 4.45B
Biogen BIIB:US $ 1984.9M 304.4M
Biomarin Pharmaceutical BMRN:US $ 461.96M 28.06M
Bristol Myers Squibb BMY:US $ 9.63B 360M
Chimerix CMRX:US 18.71M 501K
Dynavax Technologies DVAX:US $ 92.2M 43.38M
Gilead Sciences GILD:US $ 3579M 392M
Glaxosmithkline GSK:US 7.14B 722M
Gw Pharmaceuticals GWPH:US 173.49M 2.46M
Idera Pharmaceuticals IDRA:US $ 5.97M 1.59M
Merk MRK:US $ 8328M 1460M
Minerva Neurosciences NERV:US $ 7.52M 1.45M
Nektar Therapeutics NKTR:US $ 138.52M 18K
Neurocrine Biosciences NBIX:US $ 251.5M 25.4M
Novartis NOVN:VX 10.13B 319M
Pfizer PFE:US $ 16447M 3384M
Regeneron Pharmaceuticals REGN:US $ 1605.6M 185.7M
Sarepta Therapeutics SRPT:US $ 228.35M 103.31M
Tg Therapeutics TGTX:US $ 87.16M 8.12M
Vertex Pharmaceuticals VRTX:US $ 929.65M 901.68M